Dollar Tree, Inc. vs Mesoblast Limited — how do they compare? Dollar Tree, Inc. trades at $128.62 (market cap $24.61B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Dollar Tree, Inc. is far larger — about 11.1× Mesoblast Limited's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| DLTR | MESO | |
|---|---|---|
Market Cap | $24.61B | $2.21B |
Sector | Health | Technology |
52-Week High | $141.21 | $20.96 |
52-Week Low | $85.04 | $12.88 |
Enterprise Value | $31.20B | $2.21B |
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $129.37, down 1.17% today but remains in a bullish technical trend with strong support near $128. The company reported a net loss of $3.03B for 2025 due to a significant tax charge, though operating cash flow improved to $2.86B. Recent earnings have consistently beaten estimates, and a new $2.5B share repurchase program signals management confidence.
The outlook is mixed: robust cash generation and positive earnings surprises support upside, but margin pressures from tariffs and intense discount retail competition pose risks. Analyst consensus is a Buy with a $126.69 price target, slightly below current levels, indicating cautious optimism amid operational challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →